Partnering with AIM Biotech

November 4th, 2024, Vienna, Austria

We are thrilled to announce that we have partnered with Singapore-based AIM Biotech to integrate our human umbilical vein endothelial (HUVEC/TERT2) and lung fibroblast (LF/TERT309) cell lines into their microfluidic devices.

This collaboration enables more precise, human-relevant drug screening by simulating complex organ interactions, providing an advanced alternative to animal models.

Read the full PR here.